CD19 expression in matched primary and relapsed clinical samples
| Clinical subtype . | Case no., P/R . | Biopsy type . | Time between biopsy (mo) . | CD19 intensity*† . |
|---|---|---|---|---|
| DBLCL | 1P | BM | 8 | 2 |
| 1R | BM | 3 | ||
| 2P | LN | 20 | 3 | |
| 2R | Mesenteric mass | 3 | ||
| 3P | Testis | 12 | 3 | |
| 3R | Penile mass | 3 | ||
| 4P | LN | 14 | 3 | |
| 4R | LN | 3 | ||
| 5P | BM | 8 | 2 | |
| 5R | LN | 3 | ||
| MCL | 6P | Salivary gland | 20 | 3 |
| 6R | Submandibular | 3 | ||
| 7P | BM | 11 | 3 | |
| 7R | LN | 3 | ||
| 8P | LN | 15 | 3 | |
| 8R | LN | 3 | ||
| 9P | Gastrointestinal | 8 | 3 | |
| 9R | Duodenal bulb | 3 | ||
| FL | 10P | LN | 27 | 3 |
| 10R | LN | 3 | ||
| 11P | LN | 26 | 3 | |
| 11R | LN | 3 | ||
| Small/chronic LL | 12P | BM | 20 | 3 |
| 12R | BM | 2 |
| Clinical subtype . | Case no., P/R . | Biopsy type . | Time between biopsy (mo) . | CD19 intensity*† . |
|---|---|---|---|---|
| DBLCL | 1P | BM | 8 | 2 |
| 1R | BM | 3 | ||
| 2P | LN | 20 | 3 | |
| 2R | Mesenteric mass | 3 | ||
| 3P | Testis | 12 | 3 | |
| 3R | Penile mass | 3 | ||
| 4P | LN | 14 | 3 | |
| 4R | LN | 3 | ||
| 5P | BM | 8 | 2 | |
| 5R | LN | 3 | ||
| MCL | 6P | Salivary gland | 20 | 3 |
| 6R | Submandibular | 3 | ||
| 7P | BM | 11 | 3 | |
| 7R | LN | 3 | ||
| 8P | LN | 15 | 3 | |
| 8R | LN | 3 | ||
| 9P | Gastrointestinal | 8 | 3 | |
| 9R | Duodenal bulb | 3 | ||
| FL | 10P | LN | 27 | 3 |
| 10R | LN | 3 | ||
| 11P | LN | 26 | 3 | |
| 11R | LN | 3 | ||
| Small/chronic LL | 12P | BM | 20 | 3 |
| 12R | BM | 2 |
BM, bone marrow; DBLCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; LL, lymphocytic leukemia; LN, lymph node; MCL, mantle cell lymphoma; P, primary; R, relapsed.
0 = negative, 1 = weak, 2 = moderate, 3 = strong staining as determined by pathologist review.
In all samples analyzed, >80% tumor cells were CD19+.